ATE330599T1 - Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt - Google Patents
Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarktInfo
- Publication number
- ATE330599T1 ATE330599T1 AT00902628T AT00902628T ATE330599T1 AT E330599 T1 ATE330599 T1 AT E330599T1 AT 00902628 T AT00902628 T AT 00902628T AT 00902628 T AT00902628 T AT 00902628T AT E330599 T1 ATE330599 T1 AT E330599T1
- Authority
- AT
- Austria
- Prior art keywords
- acute
- angiotensin
- treatment
- myocardic
- infarct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99810061 | 1999-01-26 | ||
US46866499A | 1999-12-21 | 1999-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE330599T1 true ATE330599T1 (de) | 2006-07-15 |
Family
ID=26153740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00902628T ATE330599T1 (de) | 1999-01-26 | 2000-01-24 | Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt |
Country Status (25)
Country | Link |
---|---|
EP (2) | EP1146872B1 (de) |
JP (1) | JP2002535367A (de) |
KR (1) | KR100674053B1 (de) |
CN (1) | CN1337879A (de) |
AT (1) | ATE330599T1 (de) |
AU (1) | AU766453C (de) |
BR (1) | BR0007686A (de) |
CA (1) | CA2360691A1 (de) |
CY (1) | CY1105257T1 (de) |
CZ (1) | CZ20012682A3 (de) |
DE (1) | DE60028928T2 (de) |
DK (1) | DK1146872T3 (de) |
ES (1) | ES2265910T3 (de) |
HK (1) | HK1041808B (de) |
HU (1) | HUP0105199A3 (de) |
ID (1) | ID29818A (de) |
IL (2) | IL144216A0 (de) |
NO (1) | NO20013459L (de) |
NZ (1) | NZ513039A (de) |
PL (1) | PL197161B1 (de) |
PT (1) | PT1146872E (de) |
RU (2) | RU2298405C2 (de) |
SI (1) | SI1146872T1 (de) |
SK (1) | SK10522001A3 (de) |
WO (1) | WO2000044378A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ293257B6 (cs) * | 1998-12-23 | 2004-03-17 | Novartis Ag | Farmaceutický přípravek obsahující antagonistu receptoru AT1 pro léčení nemocí spojených s nárůstem receptorů AT1 v subepiteliální vrstvě |
WO2002017913A1 (fr) * | 2000-08-30 | 2002-03-07 | Sankyo Company, Limited | Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque |
US7076287B2 (en) | 2000-12-29 | 2006-07-11 | Ge Medical Systems Information Technologies, Inc. | System and method for detecting new left bundle branch block for accelerating treatment of acute myocardial infarction |
CA2463758A1 (en) * | 2001-10-18 | 2003-05-01 | Novartis Ag | Salts formed of an at1-receptor antagonist and a cardiovascular agent |
EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
RU2004137109A (ru) * | 2002-05-17 | 2005-10-10 | Новартис АГ (CH) | Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда |
SE0302331D0 (sv) * | 2003-08-29 | 2003-08-29 | Astrazeneca Ab | New use II |
WO2005030202A1 (en) * | 2003-09-26 | 2005-04-07 | Novartis Ag | Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders |
WO2005053687A1 (en) * | 2003-11-25 | 2005-06-16 | Novartis Ag | Combination of organic compounds |
WO2009087116A1 (en) * | 2008-01-11 | 2009-07-16 | Novartis Ag | Use of spp100 for the treatment of acute mi |
CN104086623B (zh) * | 2014-07-02 | 2017-05-24 | 牡丹江友搏药业有限责任公司 | 一种新的具有降压和细胞保护作用的化合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9027208D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
EP0577025A3 (de) * | 1992-07-01 | 1998-02-04 | Hoechst Aktiengesellschaft | Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen |
FR2716882B1 (fr) * | 1994-03-04 | 1996-04-05 | Roussel Uclaf | Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques. |
DE4432860A1 (de) * | 1994-09-15 | 1996-03-21 | Merck Patent Gmbh | Imidazopyridine |
GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
US5795904A (en) * | 1996-12-06 | 1998-08-18 | Merck & Co., Inc. | Enhanced functional recovery of the heart by losartan treatment after an ischemic attach |
-
2000
- 2000-01-24 EP EP00902628A patent/EP1146872B1/de not_active Revoked
- 2000-01-24 AU AU24397/00A patent/AU766453C/en not_active Ceased
- 2000-01-24 ID IDW00200101602A patent/ID29818A/id unknown
- 2000-01-24 SI SI200030891T patent/SI1146872T1/sl unknown
- 2000-01-24 CA CA002360691A patent/CA2360691A1/en not_active Abandoned
- 2000-01-24 EP EP06009525A patent/EP1714651A1/de not_active Withdrawn
- 2000-01-24 CN CN00803157A patent/CN1337879A/zh active Pending
- 2000-01-24 ES ES00902628T patent/ES2265910T3/es not_active Expired - Lifetime
- 2000-01-24 RU RU2001122113/15A patent/RU2298405C2/ru not_active IP Right Cessation
- 2000-01-24 KR KR1020017009327A patent/KR100674053B1/ko not_active IP Right Cessation
- 2000-01-24 SK SK1052-2001A patent/SK10522001A3/sk not_active Application Discontinuation
- 2000-01-24 IL IL14421600A patent/IL144216A0/xx active IP Right Grant
- 2000-01-24 PT PT00902628T patent/PT1146872E/pt unknown
- 2000-01-24 AT AT00902628T patent/ATE330599T1/de not_active IP Right Cessation
- 2000-01-24 DE DE60028928T patent/DE60028928T2/de not_active Revoked
- 2000-01-24 PL PL349537A patent/PL197161B1/pl not_active IP Right Cessation
- 2000-01-24 NZ NZ513039A patent/NZ513039A/en unknown
- 2000-01-24 HU HU0105199A patent/HUP0105199A3/hu unknown
- 2000-01-24 CZ CZ20012682A patent/CZ20012682A3/cs unknown
- 2000-01-24 JP JP2000595681A patent/JP2002535367A/ja not_active Withdrawn
- 2000-01-24 WO PCT/EP2000/000525 patent/WO2000044378A1/en active Application Filing
- 2000-01-24 BR BR0007686-4A patent/BR0007686A/pt not_active Application Discontinuation
- 2000-01-24 DK DK00902628T patent/DK1146872T3/da active
-
2001
- 2001-07-09 IL IL144216A patent/IL144216A/en not_active IP Right Cessation
- 2001-07-12 NO NO20013459A patent/NO20013459L/no not_active Application Discontinuation
-
2002
- 2002-02-22 HK HK02101372.4A patent/HK1041808B/zh not_active IP Right Cessation
-
2006
- 2006-09-07 CY CY20061101283T patent/CY1105257T1/el unknown
- 2006-10-05 RU RU2006135205/15A patent/RU2345790C2/ru not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0110028A (pt) | Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica | |
CY1105257T1 (el) | Χρηση των ανταγωνιστων των υποδοχεων της αγγειοτενσινης ii στην θepαπεια του οξεος εμφραγματος του μυοκαρδιου | |
ATE334668T1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
DE60039783D1 (de) | Lfa-1 antagonisten und tnf-alpha antagonisten zur | |
NO20034311D0 (no) | CCR5-antagonister for behandling av AIDS | |
NO963064L (no) | Behandling av normotensive glaukoma med angiotensin-II-antagonister | |
DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
MY124786A (en) | Bis-arylsulfones | |
DE69432595D1 (de) | Antagonisten des angiotensin ii-rezeptors zur behandlung von chronischen entzündlichen erkrankungen | |
ATE324890T1 (de) | Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck | |
CY1106365T1 (el) | Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου | |
EE200100520A (et) | N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena | |
AP2002002501A0 (en) | Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog. | |
EE200100553A (et) | Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks | |
EA200601592A1 (ru) | Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора | |
BR0000486A (pt) | Antagonistas do neuropeptìdeo y | |
DE60009315D1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
EA200401617A1 (ru) | Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера | |
NO20033634L (no) | GLyT-1-inhibitorer | |
ATE316374T1 (de) | Antikonvulsive derivate zur behandlung von essentiellem tremor | |
DE69732492D1 (de) | Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden | |
DE69923982D1 (de) | Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten | |
ATE293975T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von kognitiven störungen | |
NO981188D0 (no) | 5-HT3-reseptorantagonister for dyskinesi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1146872 Country of ref document: EP |
|
RZN | Patent revoked |